10 More Korean Rights Issues: One Diluted 17.3%, Another 61.6%
A fresh batch of filings, late August through mid-September: the largest raise (Samsung FN REIT, ₩97.7bn) diluted shareholders 17.3%. The second-largest (Heng Sheng Holding Group, ₩60.0bn) diluted them 61.6%. Not advice.
AI-assisted, human-reviewed sourcing. Figures are pulled programmatically from the official sources listed at the end of this article and checked by an editor before publication.
rights issuedilutiondartkoreacapital raising
Three weeks ago we ranked 35 Korean capital-raising filings and found that the size of the deal did not predict what it meant for the shareholders already holding the stock. A fresh batch of rights-issue filings, unconnected to that first one, says the same thing again.
Ten filings, 26 August-11 September
| Company | Ticker | Raised | Dilution |
|---|---|---|---|
| Samsung FN REIT | 448730 | ₩97.7bn | 17.3% |
| Heng Sheng Holding Group | 900270 | ₩60.0bn | 61.6% |
| Taeyoung E&C | 009410 | ₩50.5bn | 6.8% |
| HLB innoVation | 024850 | ₩36.0bn | 8.0% |
| VUNO | 338220 | ₩31.4bn | 31.0% |
| Nexa Dynamics | 351320 | ₩30.0bn | 25.0% |
| Jincostech | 250030 | ₩16.6bn | 22.8% |
| FINO | 033790 | ₩15.0bn | 3.1% |
| Satoshi Holdings | 223310 | ₩7.0bn | 36.0% |
| KS Industry | 101000 | ₩6.0bn | 33.0% |
Line the ten up by size and the dilution column does not follow. Samsung FN REIT raised the most of the ten, ₩97.7bn, and diluted existing holders 17.3% — middle of the pack. Heng Sheng Holding Group, the second-largest raise at ₩60.0bn, diluted holders 61.6%, more than any other company here. The lowest dilution in the batch, FINO’s 3.1%, belongs to a company that raised ₩15.0bn — smaller than seven of the other nine.
One detail worth flagging on its own
Heng Sheng Holding Group’s ticker, 900270, sits in the block Korea Exchange reserves for foreign-incorporated companies — mostly Chinese firms — listed on KOSDAQ. We’re not drawing a conclusion from that fact; we’re stating it because a reader comparing this company to the other nine, all domestically incorporated, should know the listing is a different kind of company on a structural level, not just a different sector.
What we left out, and why
Two of the largest filings in this same window don’t appear in the table: Samsung Biologics (₩3.0tn, 4.7% dilution), which we already covered as its own story, and H&L Advanced (₩1.2tn). H&L Advanced filed the identical report type as the ten companies above, but DART lists it with no stock code — it is not a listed, tradeable company, so a “dilution” percentage for it doesn’t mean what it means for a stock a reader could actually buy or sell. We dropped it, and a real-estate trust filing in the same window with the same problem, for that reason rather than compute a number that looks comparable but isn’t.
The pattern holds
This is the second time, with two unconnected batches of filings three weeks apart, that lining up Korean capital raises by size has told us nothing about what they do to existing shareholders. Ten filings is still not a large enough sample to prove that statistically — but it is a second data point in the same direction, and we’re reporting it as exactly that: a second data point, not a proof.
These are statistics, not you. This is not investment advice.
Data & Verification Notes
- Data as of
- Sources
- DART (Financial Supervisory Service electronic disclosure) — Rights-issue decisions (piicDecsn), ten filings by listed companies, 26 August-11 September 2026 — computed the same way as our earlier capital-raising work: dilution = new shares / (new shares + existing shares), amount raised = sum of the reported use-of-proceeds fields (facility, operating, debt repayment, business acquisition, other)
- Cross-checks
- Sorted by amount raised, largest first: Samsung FN REIT ₩97.7bn (17.3% dilution) · Heng Sheng Holding Group ₩60.0bn (61.6%) · Taeyoung E&C ₩50.5bn (6.8%) · HLB innoVation ₩36.0bn (8.0%) · VUNO ₩31.4bn (31.0%) · Nexa Dynamics ₩30.0bn (25.0%) · Jincostech ₩16.6bn (22.8%) · FINO ₩15.0bn (3.1%) · Satoshi Holdings ₩7.0bn (36.0%) · KS Industry ₩6.0bn (33.0%).
- The largest filing here (Samsung FN REIT, ₩97.7bn) sits in the bottom half by dilution. The lowest-dilution filing (FINO, 3.1%) raised the eighth-largest amount of the ten, not the largest. The highest-dilution filing (Heng Sheng, 61.6%) is the second-largest raise, not the smallest.
- Heng Sheng Holding Group trades under a 900-series ticker (900270) — the block Korea Exchange reserves for foreign-incorporated companies, mostly Chinese, listed on KOSDAQ.
- This matches the pattern our 2 September report found across 35 filings in three instruments: the size of a capital raise did not predict its dilution or cancellation terms there either.
- Excluded figures
- Samsung Biologics, which filed a rights issue in the same window (₩3.0tn, 4.7% dilution). We covered that filing on its own already; including it here would dwarf this batch's chart without adding a new data point.
- H&L Advanced (₩1.2tn, computed 6.2%) and 민간임대허브제4호 (a private real-estate trust, ₩144.9bn, 22%). Both filed the same rights-issue report type, but neither has a stock code — DART classifies them as unlisted — so there is no tradeable share count for 'dilution' to mean the same thing as it does for the ten companies above.
- Ingrid (이노그리드), for the same reason: no stock code in DART's company record.
- Volvik, whose filing did not report a pre-issue share count we could use to compute a dilution percentage, so we left it out rather than estimate one.
- Any correlation test. Ten filings, like the 21 in our earlier piece, is a pattern shown side by side, not a sample large enough to prove one statistically.
- Any view on whether these are good or bad filings for existing shareholders. This reports what ten listed companies filed; it is not investment advice.
- Instruments
- 448730, 900270, 009410, 024850, 338220, 351320, 250030, 033790, 223310, 101000
The full dataset behind these figures — every listed company, every row — is available to license. SeoulMarkets data for licence →
Not investment advice. SMarkets publishes data journalism for general information only. Nothing here is investment advice, a recommendation, or an offer to buy or sell any security — any investment you make is at your own risk and responsibility. Figures are derived from official public data sources and may be revised by the issuing agency. Verify independently before acting.
← More Equities